Home › Non-Small Cell Lung Cancer › NCT05502523

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

The Impact of Surgical Technique on Circulating Tumor DNA in Early-Stage Non-Small Cell Lung Cancer

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC
* Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease

Exclusion Criteria:

* Previous cancer diagnosis within 5 years (except ductal carcinoma in situ \[DCIS\] of the breast, superficial bladder cancer, non-melanoma skin primary, other malignancy that does not require treatment).
* Preoperative chemotherapy, immunotherapy, or radiation therapy
* Receipt of perioperative blood transfusion

About the study

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.

What is being tested

• Pulmonary Artery-First Surgical Technique (procedure)
• Biospecimen Collection (procedure)

Sponsor: Thomas Jefferson University · Participants: 100 · Started: Aug 31, 2022

Contact the study team

• Tyler Grenda, MD · Phone: 215-955-5562

Official record on ClinicalTrials.gov — NCT05502523

Locations in the U.S.

Conditions

• Non-Small Cell Lung Cancer
• Lung Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.